Flashpoint Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Flashpoint Therapeutics General Information

Description

Developer of cancer immunotherapies intended to optimize anti-tumor immune response. The company nanostructures are formulations that kinetically tune and co-deliver precise combinations of therapeutic components with nanoscale presentation optimized to induce a powerful, coordinated anti-tumor immune response, enabling patients to have a new approach to designing potent cancer immunotherapies that transform therapeutic components from ineffective to curative through optimized nanoscale architecture.

Contact Information

Website
www.flashpoint.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1801 Maple Avenue
  • Evanston, IL 60201
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, HealthTech, Life Sciences, Oncology
Corporate Office
  • 1801 Maple Avenue
  • Evanston, IL 60201
  • United States

Flashpoint Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Flashpoint Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 01-Feb-2024 Completed Clinical Trials - Phase 2
2. Seed Round 17-Oct-2023 Completed Clinical Trials - Phase 2
1. University Spin-Out 01-Jan-2022 Completed Clinical Trials - Phase 2
To view Flashpoint Therapeutics’s complete valuation and funding history, request access »

Flashpoint Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed-2
Seed-1
To view Flashpoint Therapeutics’s complete cap table history, request access »

Flashpoint Therapeutics Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Flashpoint Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220088059-A1 Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy Inactive 12-Feb-2019
US-11696954-B2 Synthesis of spherical nucleic acids using lipophilic moieties Active 28-Apr-2017
US-20200188521-A1 Synthesis of spherical nucleic acids using lipophilic moieties Active 28-Apr-2017
US-20200248183-A1 Tlr9-targeted spherical nucleic acids having potent antitumor activity Inactive 03-Apr-2017
US-11866700-B2 Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna Active 06-May-2016 C12N15/113
To view Flashpoint Therapeutics’s complete patent history, request access »

Flashpoint Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Flashpoint Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
The Querrey InQbation Lab Accelerator/Incubator
Beta Lab Accelerator/Incubator Minority
CS Venture Opportunities Fund Venture Capital Minority
Northwestern University University
To view Flashpoint Therapeutics’s complete investors history, request access »

Flashpoint Therapeutics Investments (1)

Flashpoint Therapeutics’s most recent deal was a Corporate Asset Purchase with Exicure (Technology, Research and Development Programs and Clinical Assets) for . The deal was made on 27-Sep-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Exicure (Technology, Research and Development Programs and Clinical Assets) 27-Sep-2024 Corporate Asset Purchase Buildings and Property
To view Flashpoint Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial

Flashpoint Therapeutics FAQs

  • When was Flashpoint Therapeutics founded?

    Flashpoint Therapeutics was founded in 2022.

  • Where is Flashpoint Therapeutics headquartered?

    Flashpoint Therapeutics is headquartered in Evanston, IL.

  • What is the size of Flashpoint Therapeutics?

    Flashpoint Therapeutics has 7 total employees.

  • What industry is Flashpoint Therapeutics in?

    Flashpoint Therapeutics’s primary industry is Drug Discovery.

  • Is Flashpoint Therapeutics a private or public company?

    Flashpoint Therapeutics is a Private company.

  • What is Flashpoint Therapeutics’s current revenue?

    The current revenue for Flashpoint Therapeutics is .

  • How much funding has Flashpoint Therapeutics raised over time?

    Flashpoint Therapeutics has raised $10M.

  • Who are Flashpoint Therapeutics’s investors?

    The Querrey InQbation Lab, Beta Lab, CS Venture Opportunities Fund, and Northwestern University have invested in Flashpoint Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process